Quest Diagnostics (NYSE: DGX) director adds shares through dividend reinvestment
Rhea-AI Filing Summary
Quest Diagnostics director Robert B. Carter reported a small acquisition of 11 shares of common stock on July 22, 2026 at $206.804 per share. The shares were acquired through a broker-administered dividend reinvestment plan under Rule 16a-6, bringing his direct holdings to 3,864 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 11 shares
Net Buy
1 txn
Insider
CARTER ROBERT B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Small Acquisition | Common Stock F1 | 11 | $206.804 | $2K |
Holdings After Transaction:
Common Stock — 3,864 shares (Direct)
Footnotes (1)
- F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Shares acquired: 11 shares
Acquisition price: $206.804 per share
Holdings after transaction: 3,864 shares
3 metrics
Shares acquired
11 shares
Common stock acquired on July 22, 2026 under dividend reinvestment plan
Acquisition price
$206.804 per share
Price for the 11 Quest Diagnostics common shares acquired
Holdings after transaction
3,864 shares
Total direct Quest Diagnostics common stock held by Robert B. Carter after acquisition
Key Terms
dividend reinvestment plan, Rule 16a-6, Form 5, small acquisition
4 terms
dividend reinvestment plan financial
"acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker"
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
Rule 16a-6 regulatory
"eligible for deferred reporting on Form 5 under Rule 16a-6"
Form 5 regulatory
"eligible for deferred reporting on Form 5 under Rule 16a-6"
A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.
small acquisition regulatory
"transaction code description: Small acquisition under Rule 16a-6"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Quest Diagnostics (DGX) report for Robert B. Carter?
Quest Diagnostics director Robert B. Carter reported acquiring 11 shares of common stock. The transaction occurred on July 22, 2026 through a broker-administered dividend reinvestment plan and was eligible for deferred reporting on Form 5 under Rule 16a-6.
How was the Quest Diagnostics (DGX) insider transaction executed?
The transaction involved shares acquired under a dividend reinvestment plan run by the reporting person’s broker. It qualified for deferred reporting on Form 5 under Rule 16a-6, but the director chose to disclose it early in this insider report.
Is the recent DGX insider transaction part of a Rule 16a-6 small acquisition?
Yes. The filing classifies the 11-share purchase as a small acquisition under Rule 16a-6. Such transactions can be reported later on Form 5, but in this case were voluntarily reported earlier on an insider ownership report.